NEW research employing Mendelian randomisation (MR) analysis has identified a potential causal relationship between lipid ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), next-generation biopharma dedicated to the ...

In this randomized controlled trial, among patients with persistent chylomicronemia, it was found that plozasiran more ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

A team of Ohio University researchers have made a groundbreaking development in the fight against obesity. In a study ...

Scientists at Ohio University have identified a protein that could help fight obesity by improving metabolism and preventing ...

Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next generation biopharma company dedicated to ...

A medical expert explained the non-pharmaceutical ways to lower cholesterol levels after a patient said they didn't like the ...